<p>大多數投資者會將財報公告視為過去的事件，將當前股票價格的波動與結果聯繫起來，認為現在已經太晚而無法採取行動。這可能是 <strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> 股票的情況，因為在公司公佈季度財報後的早晨，該股上漲超過 6%。</p>
<p>儘管這是公司今年最好的日子之一，但報告中有跡象表明，即使在財報反應之後，Hims &amp; Hers 的股票今天也是一個買入機會。這些理由大多源於公司的基本面，但並不僅限於此。行業趨勢將為投資者提供一種緩衝未來經濟可能出現的情況的優選方式。</p>
<p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<p>如果通貨膨脹的威脅最終成為美國的現實，可以根據 <strong>iShares 20+ Year Treasury Bond ETF NASDAQ: TLT</strong> 與 <strong>iShares Russell 2000 ETF NYSEARCA: IWM</strong> 等股票指數的表現來判斷，二者在預期通貨膨脹上升時的歷史表現存在分歧。作為醫療保健行業的一部分，Hims &amp; Hers 的股票為市場提供了安全性，同時也受益於技術領域的高利潤特性。</p>
<h2><strong>Hims &amp; Hers 股票今天所有關鍵績效指標表現強勁</strong></h2>
<p>雖然單日上漲 6% 可能看起來足夠看漲，但與公司關鍵績效指標（KPI）所顯示的增長率相比，這仍然相形見絀。從收入開始，Hims &amp; Hers 報告本季度收入大幅躍升至 4.016 億美元，比去年同期增長 77%。</p>
<p>用户增長，更重要的是用户變現，推動了公司的收入。因此，觀察 Hims &amp; Hers 的用户，投資者將看到公司用户數量達到 200 萬，推動年增長率達到高達 44% 的兩位數增長。</p>
<p>然而，如果沒有適當的變現系統來使這些用户改變公司的底線，用户增長將毫無意義。Hims &amp; Hers 在這方面沒有問題，因為他們報告每位訂閲者的平均在線收入達到 67 美元，較去年同期的 54 美元增長，年增長率為 24%。</p>
<h3>Hims &amp; Hers Health, Inc. (HIMS) 2024 年 11 月 6 日的價格走勢圖</h3>
<p>投資者應該對 Hims &amp; Hers 的商業模式感到興奮。由於其主要依賴訂閲，分析師可以更好地預測未來的財務狀況，因為訂閲更穩定且可預測，這在醫療保健行業是典型的。但這就是作為技術平台運營的好處所在。</p>
<p>得益於其運營模式，Hims &amp; Hers 的股票毛利率高達 80%，高於行業平均水平。這些高利潤率，加上兩位數的收入和用户增長，使管理層能夠保留更多公司的資本用於進一步的增長投資。</p>
<p>這就是未來的假設。然而，這些趨勢的當前好處反映在公司的經營現金流中，本季度增長至 8530 萬美元，比去年同期的 2520 萬美元增長了 238%。</p>
<p>所有這些將轉化為投資者最關心的指標之一：每股收益（EPS）。與去年同期每股淨虧損 0.04 美元相比，Hims &amp; Hers 本季度每股收益達到 0.35 美元，這一增長只是對結果反應的 6% 上漲的一小部分。</p>
<h2><strong>華爾街對 Hims &amp; Hers 股票的看漲觀點：未來展望</strong></h2>
<p>從最近的華爾街分析師情緒開始，投資者可以看到八位分析師對 Hims &amp; Hers 股票給予買入評級，但價格目標才是未來指導的關鍵。Canaccord Genuity Group 決定將該股的目標價定為每股 28 美元，這意味着他們認為從今天的價格來看還有高達 32% 的上漲空間。</p>
<p>當然，這些估值尚未反映公司的新業績，也未考慮可能提升股票未來價值的每股收益增長。然而，一些機構投資者提前採取了這一觀點。</p>
<p>來自 Principal Financial Group 的買家決定在 2024 年 10 月將其在 Hims &amp; Hers 股票中的持股增加多達 102%，使其淨頭寸今天達到 540 萬美元。這向零售投資者傳達了強烈的信心信息。</p>
<p>最後一個指標可以從 Hims &amp; Hers 股票今天的估值與行業其他股票的比較中得出。在市淨率（P/B）基礎上，Hims &amp; Hers 股票的交易倍數高達 12.9 倍，顯著高於醫療行業目前的平均水平 4.7 倍。</p>
<p>有人可能會認為這很昂貴且過度擴張，但現實是，市場會為他們相信能夠在不久的將來表現優於其他股票的股票支付溢價，而這種信念是由 Hims &amp; Hers 今天業績所顯示的增長率所證明的。</p>
<p>→ Tim Sykes 的緊急交易提醒：“立即採取行動”（來自 Timothy Sykes）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE1OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE1OA"/></p>
<h2>你現在應該投資 1000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>查看這五隻股票的詳情</p>

HIMS

<p>分析師建議，儘管在財報發佈後股價上漲了 6%，Hims & Hers 的股票仍然值得購買。該公司報告的收入增長了 77%，達到 5060 萬美元，運營現金流增長了 238%。Hims & Hers 在醫療保健領域的毛利率為 80%，用户基礎不斷增長，處於良好的市場位置。八位分析師推薦買入，目標價顯示出潛在的 32% 上漲空間。該公司的訂閲模式提供了穩定性，使其成為一個有吸引力的投資選擇</p>

<p>Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, thinking that it is now too late to get into action. This might be the case for shares of <strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong>, as the stock is now rallying by over 6% the morning after the company reported its quarterly earnings.</p>
<div class="lb-trans"><p>大多數投資者會將財報公告視為過去的事件，將當前股票價格的波動與結果聯繫起來，認為現在已經太晚而無法採取行動。這可能是 <strong>Hims &amp; Hers Health Inc. NYSE: HIMS</strong> 股票的情況，因為在公司公佈季度財報後的早晨，該股上漲超過 6%。</p>
</div><p>Even though this is one of the company's best days this year, there are signs within the report that make Hims &amp; Hers stock a Buy today, even after the earnings reaction. Most of these reasons are found in the company’s fundamentals, but it doesn’t end there. Industry trends will offer investors a preferred way to cushion what might come to the economy in the near future.</p>
<div class="lb-trans"><p>儘管這是公司今年最好的日子之一，但報告中有跡象表明，即使在財報反應之後，Hims &amp; Hers 的股票今天也是一個買入機會。這些理由大多源於公司的基本面，但並不僅限於此。行業趨勢將為投資者提供一種緩衝未來經濟可能出現的情況的優選方式。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><p>If the threats of inflation end up becoming a reality for the United States, judging by how assets like the <strong>iShares 20+ Year Treasury Bond ETF NASDAQ: TLT</strong> behave against stock indexes like the <strong>iShares Russell 2000 ETF NYSEARCA: IWM</strong>, diverging in the ways that it historically does when inflation is expected to rise. By operating in the healthcare sector, Hims &amp; Hers stock offers safety to the markets, along with the high margin nature of the technology space.</p>
<div class="lb-trans"><p>如果通貨膨脹的威脅最終成為美國的現實，可以根據 <strong>iShares 20+ Year Treasury Bond ETF NASDAQ: TLT</strong> 與 <strong>iShares Russell 2000 ETF NYSEARCA: IWM</strong> 等股票指數的表現來判斷，二者在預期通貨膨脹上升時的歷史表現存在分歧。作為醫療保健行業的一部分，Hims &amp; Hers 的股票為市場提供了安全性，同時也受益於技術領域的高利潤特性。</p>
</div><h2><strong>All Key Performance Indicators Running Hot for Hims &amp; Hers Stock Today</strong></h2>
<div class="lb-trans"><h2><strong>Hims &amp; Hers 股票今天所有關鍵績效指標表現強勁</strong></h2>
</div><p>While a 6% rally in a single day might seem bullish enough, it doesn't come close to what should be compared to the growth rates seen in the company's key performance indicators (KPIs). Starting with revenue, Hims &amp; Hers reported a massive jump to $401.6 million for the quarter, a boost of 77% over the same quarter last year.</p>
<div class="lb-trans"><p>雖然單日上漲 6% 可能看起來足夠看漲，但與公司關鍵績效指標（KPI）所顯示的增長率相比，這仍然相形見絀。從收入開始，Hims &amp; Hers 報告本季度收入大幅躍升至 4.016 億美元，比去年同期增長 77%。</p>
</div><p>User growth and, more importantly, user monetization drives the company's revenue. So, looking at users for Him &amp; Hers, investors will see the company reaching up to 2 million users, pushing for another double-digit growth rate of as high as 44% in the year.</p>
<div class="lb-trans"><p>用户增長，更重要的是用户變現，推動了公司的收入。因此，觀察 Hims &amp; Hers 的用户，投資者將看到公司用户數量達到 200 萬，推動年增長率達到高達 44% 的兩位數增長。</p>
</div><p>However, user growth would be nothing without the proper monetization system to get these users to change the company's bottom line. Hims &amp; Hers has no issue with this, as they reported up to $67 of average online revenue per subscriber, up from $54 in the same quarter last year, translating into a 24% jump over the year.</p>
<div class="lb-trans"><p>然而，如果沒有適當的變現系統來使這些用户改變公司的底線，用户增長將毫無意義。Hims &amp; Hers 在這方面沒有問題，因為他們報告每位訂閲者的平均在線收入達到 67 美元，較去年同期的 54 美元增長，年增長率為 24%。</p>
</div><h3>Hims &amp; Hers Health, Inc. (HIMS) Price Chart for Wednesday, November, 6, 2024</h3>
<div class="lb-trans"><h3>Hims &amp; Hers Health, Inc. (HIMS) 2024 年 11 月 6 日的價格走勢圖</h3>
</div><p>Investors should get excited about Hims &amp; Hers' business model here. As it depends mostly on subscriptions, analysts can better project future financials as subscriptions are more stable and predictable, which is typical of the healthcare sector. But here is where the benefits of operating as a technology platform come into play.</p>
<div class="lb-trans"><p>投資者應該對 Hims &amp; Hers 的商業模式感到興奮。由於其主要依賴訂閲，分析師可以更好地預測未來的財務狀況，因為訂閲更穩定且可預測，這在醫療保健行業是典型的。但這就是作為技術平台運營的好處所在。</p>
</div><p>Thanks to its operating model, Hims &amp; Hers stock has a gross profit margin of up to 80%, which is above the industry average. These high margins, coupled with double-digit revenue and user growth, enable management to retain more of the company's capital for reinvestment into further growth.</p>
<div class="lb-trans"><p>得益於其運營模式，Hims &amp; Hers 的股票毛利率高達 80%，高於行業平均水平。這些高利潤率，加上兩位數的收入和用户增長，使管理層能夠保留更多公司的資本用於進一步的增長投資。</p>
</div><p>That's the future assumption. However, the present benefits from these trends are reflected in the company's operating cash flows, which grew to a high of $85.3 million for the quarter, a 238% jump from the $25.2 million generated during the same quarter last year.</p>
<div class="lb-trans"><p>這就是未來的假設。然而，這些趨勢的當前好處反映在公司的經營現金流中，本季度增長至 8530 萬美元，比去年同期的 2520 萬美元增長了 238%。</p>
</div><p>All of this would translate into one of the metrics that investors tend to care about the most: earnings per share (EPS). Compared to a net loss per share of $0.04 for the same quarter last year, Hims &amp; her stock delivered up to $0.35 in EPS this quarter, an ump that is a fraction of the 6% rally that came as a reaction to the results.</p>
<div class="lb-trans"><p>所有這些將轉化為投資者最關心的指標之一：每股收益（EPS）。與去年同期每股淨虧損 0.04 美元相比，Hims &amp; Hers 本季度每股收益達到 0.35 美元，這一增長只是對結果反應的 6% 上漲的一小部分。</p>
</div><h2><strong>Wall Street’s Bullish Take on Hims &amp; Hers Stock: What the Future Holds</strong></h2>
<div class="lb-trans"><h2><strong>華爾街對 Hims &amp; Hers 股票的看漲觀點：未來展望</strong></h2>
</div><p>Starting with the recent Wall Street analyst sentiment, investors can see eight analysts pushing for a Buy rating in Hims &amp; Hers stock, but the price target is what matters here for future guidance. Those at Canaccord Genuity Group decided to place a $28 a share price target for the stock, meaning they see up to 32% more upside from today’s price.</p>
<div class="lb-trans"><p>從最近的華爾街分析師情緒開始，投資者可以看到八位分析師對 Hims &amp; Hers 股票給予買入評級，但價格目標才是未來指導的關鍵。Canaccord Genuity Group 決定將該股的目標價定為每股 28 美元，這意味着他們認為從今天的價格來看還有高達 32% 的上漲空間。</p>
</div><p>Of course, these valuations don’t reflect the company's new results yet, nor do they take into account the potential EPS growth that might boost the stock’s value in the future. However, some institutional buyers decided to take this view ahead of time.</p>
<div class="lb-trans"><p>當然，這些估值尚未反映公司的新業績，也未考慮可能提升股票未來價值的每股收益增長。然而，一些機構投資者提前採取了這一觀點。</p>
</div><p>Buyers from Principal Financial Group decided to boost their holdings in Hims &amp; Hers stock by as much as 102% as of October 2024, bringing their net position to a high of $5.4 million today. This sends a strong confidence message for retail investors to consider today.</p>
<div class="lb-trans"><p>來自 Principal Financial Group 的買家決定在 2024 年 10 月將其在 Hims &amp; Hers 股票中的持股增加多達 102%，使其淨頭寸今天達到 540 萬美元。這向零售投資者傳達了強烈的信心信息。</p>
</div><p>The last gauge can be taken from Hims &amp; Hers stock’s valuation today, compared to the rest of the sector. On a price-to-book (P/B) basis, Hims &amp; Hers stock trades at a high 12.9x multiple, significantly above the medical sector’s average of 4.7x today.</p>
<div class="lb-trans"><p>最後一個指標可以從 Hims &amp; Hers 股票今天的估值與行業其他股票的比較中得出。在市淨率（P/B）基礎上，Hims &amp; Hers 股票的交易倍數高達 12.9 倍，顯著高於醫療行業目前的平均水平 4.7 倍。</p>
</div><p>Some may call this expensive and overextended, but the reality is that markets will overpay for stocks they believe can outperform in the near future, and that belief is justified by the growth rates seen in Hims &amp; Hers' results today.</p>
<div class="lb-trans"><p>有人可能會認為這很昂貴且過度擴張，但現實是，市場會為他們相信能夠在不久的將來表現優於其他股票的股票支付溢價，而這種信念是由 Hims &amp; Hers 今天業績所顯示的增長率所證明的。</p>
</div><p>→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes)(Ad)</p>
<div class="lb-trans"><p>→ Tim Sykes 的緊急交易提醒：“立即採取行動”（來自 Timothy Sykes）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE1OA" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10158&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Hims &amp; Hers Health right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票的詳情</p>
</div>

Hims & Hers Health：為什麼這隻醫療股的增長使其值得買入